Tus nqi ntawm Circulating Exosomal PD-L1 nyob rau hauv Kev Ntsuas Thiab Kev Kho Mob ntawm Malignant Tumors

Hu rau:joanna.jia@wecistanche.com/ WhatsApp: 008618081934791

Exosomal PD-L1 tau pom tias yog ib qho tseem ceeb ua rau mob qog noj ntshav. Ob qho tib si hauv vitro thiab hauv vivo kev sim tau lees paub tias PD-L1 ntxiv rau exosomes tuaj yeem cuam tshuam cov lymphocyte muaj nuj nqi thiab txhawb cov qog cell proliferation. Yog li ntawd, theem ntawm exosomal PD-L1 feem ntau cuam tshuam nrog kev loj hlob ntawm tus kab mob thiab kev kwv yees ntawm cov neeg mob qog nqaij hlav, nrog rau cov nyhuv ntawm kev tiv thaiv PD1 immunotherapy.

Cistancheyog ibzoo anti-tumor tshuaj ntsuab raucov neeg mobnrogmalignant qog

1 Circulating exosomal PD-L1 thiab immunotherapy

Raws li ib yam tshiab ntawm malignant qog kho mob, immunotherapy, rau ib tug tej yam, ua rau cov shortcomings ntawm ib txwm kev kho mob txoj kev thiab yog ib tug cog lus kev kho mob rau malignant qog. Tumor immunotherapy tuaj yeem cuam tshuam lossis tshem tawm cov qog hlwb los ntawm kev txhim kho lossis ua kom cov nyhuv tua cov lymphocytes ntawm cov qog hlwb. Tam sim no, FDA pom zoo cov qog immunotherapies suav nrog tshuaj tiv thaiv kab mob qog noj ntshav, cytokines, tshuaj tiv thaiv CTLA-4 tshuaj tiv thaiv, CAR-T kho, thiab tshuaj tiv thaiv PD1 / PD-L1 tshuaj tiv thaiv kab mob. Ntawm lawv, anti-PD1 / PD-L1 antibody therapy tau dhau los ua txoj kev kho mob tseem ceeb ntawm kev tiv thaiv kab mob vim nws lub hom phiaj siab teb tus nqi, cov kev mob tshwm sim tsawg dua, thiab tsim nyog rau ntau hom qog nqaij hlav. Clinically, seb cov neeg mob qog nqaij hlav puas tsim nyog rau kev kho mob los tiv thaiv PD1 feem ntau yog qhia los ntawm histopathological PD-L1 nrhiav pom, tab sis cov ntaub so ntswg feem ntau nyuaj kom tau, thiab cov qauv hauv zos yog qhov nyuaj kom tsis txhob muaj teeb meem ntawm cov qog heterogeneity. Tsis tas li ntawd, cov kev tshawb fawb tau pom tias cov neeg mob uas nws cov ntaub so ntswg yog PD-L1-tsis zoo kuj tseem tuaj yeem tsim ntau tus PD-L1-exosomes zoo. Piv nrog rau cov ntaub so ntswg PD-L1 tshawb pom, kev tshawb pom ntawm cov kab mob exosomal PD-L1 tuaj yeem ua tiav cov qauv tsis muaj kev cuam tshuam, tshawb pom lub sijhawm tiag tiag, thiab zam qhov teeb meem ntawm qog heterogeneity tshwm sim los ntawm kev kuaj hauv zos. Yog li, circulating exosomal PD-L1 yuav tsum dhau los ua tus cim tshiab rau kev tiv thaiv PD1 immunotherapy. Ib txoj kev tshawb nrhiav uas pom cov kab mob exosomal PD-L1 protein nyob rau hauv cov neeg mob melanoma coj kev kho mob los tiv thaiv PD1 ua ntej kev kho mob pom tau tias cov neeg mob uas tsis teb rau kev kho mob yuav muaj ntau theem ntawm circulating exosomal PD-L1, thaum uas tsis muaj theem ntawm circulating exosomal PD-L1. tau pom. Cov neeg mob uas muaj exosomal PD-L1 feem ntau pom cov lus teb ua tiav lossis cov lus teb ib nrab. Hauv kev tshawb fawb ntawm melanoma thiab cov qog nqaij hlav tsis me me hauv lub ntsws, nws kuj tau pom tias theem qhia ntawm kev nthuav tawm exosomal PD-L1 mRNA cuam tshuam nrog cov lus teb ntawm cov neeg mob rau kev kho mob los tiv thaiv PD1. Kev txo qis, tab sis tsis txo qis hauv pawg kab mob ruaj khov, thiab nce ntxiv hauv pawg kab mob uas tsis zoo. Yog li, nws ntseeg tau tias kev tshawb pom ntawm exosomal PD-L1 hauv cov neeg mob tau txais kev kho mob los tiv thaiv PD1 tuaj yeem pab kwv yees lawv cov txiaj ntsig.

Anti-mobKev kho mob: anti-PD1 txoj kev kho & Cistanche deserticola

2 Circulating exosomal PD-L1 thiab kuaj qog

Exosomal PD-L1 can assist the immune escape of malignant tumor cells by inhibiting the function of CD8+ T cells and promoting disease progression. Therefore, circulating exosomal PD-L1 levels may also reflect the disease status of patients with malignant tumors. In a clinical study including 40 patients with head and neck squamous cell carcinoma, it was found that the level of circulating exosomal PD-L1 was highly correlated with tumor stage and lymph node metastasis status (P=0.0008, 0.013). It can indirectly reflect the disease progression and immune function of patients and can be used as a monitoring index for the condition of head and neck squamous cell carcinoma. Studies have also found that serum exosomal PD-L1 levels are correlated with parameters such as tumor size, lymph node metastasis and distant metastasis status in non-small cell lung cancer, and compared with patients with low levels of serum exosomal PD-L1, high levels of PD-L1. Patients with larger tumor volume (>2.5 cm) (P<0.001) were="" more="" prone="" to="" lymph="" node="" metastasis="" and="" distant="" metastasis=""><0.05). therefore,="" monitoring="" serum="" exosomal="" pd-l1="" levels="" has="" a="" predictive="" value="" for="" the="" disease="" status="" of="" patients="" with="" non-small="" cell="" lung="" cancer.="" in="" addition,="" the="" changing="" level="" of="" circulating="" exosomal="" pd-l1="" before="" and="" after="" treatment="" (δexopd-l1)="" also="" has="" important="" clinical="" value.="" a="" study="" included="" 100="" patients="" with="" melanoma.="" by="" detecting="" the="" δexopd-l1="" level="" of="" patients="" before="" and="" after="" treatment="" and="" analyzing="" its="" relationship="" with="" the="" progression="" of="" melanoma="" after="" treatment,="" the="" results="" showed="" that="" the="" δexopd-l1="" level="" of="" patients="" with="" progression="" after="" treatment="" was="" higher="" than="" that="" of="" patients="" without="" progression="" after="" treatment.="" the="" sensitivity="" and="" specificity="" were="" 83%="" and="" 70%,="" respectively="" when="" δexopd-l1="">100 tau siv los ua tus nqi txiav tawm los kuaj mob melanoma tom qab kho.

Anti-tumor tsoos suav tshuaj tshuaj ntsuab: Desertiliving Cistanche nroj tsuag

3 Circulating exosomal PD-L1 thiab qog prognosis

Exosomal PD-L1 ua lub luag haujlwm tseem ceeb hauv kev txhawb nqa kev loj hlob ntawm cov qog nqaij hlav, yog li nws feem ntau ua rau cov neeg mob tsis zoo. Kev txheeb xyuas ntawm nws qib kuj tseem muaj txiaj ntsig zoo hauv kev txiav txim siab txog kev kwv yees. Ib txoj kev tshawb fawb suav nrog 69 tus neeg mob uas muaj mob qog noj ntshav thiab pom tias cov ntshav plasma preoperative exosomal PD-L1 qib tau cuam tshuam nrog cov neeg mob prognosis. Kev ciaj sia tag nrho ntawm cov neeg mob tau luv luv (P=0.004), thiab kev soj ntsuam kev ciaj sia tau pom tias cov ntshav plasma exosomal PD-L1 yog qhov ua rau muaj kev ywj pheej (P=0.026). Circulating exosomal PD-L1 kuj tau pom qee qhov muaj peev xwm hauv kev kwv yees kwv yees tom qab kho. Ib txoj kev tshawb fawb suav nrog 55 tus neeg mob uas muaj mob qog noj ntshav thiab kuaj pom lawv cov ntshav exosomal PD-L1 ua ntej kev phais, thiab pom tias piv nrog cov neeg mob uas muaj cov kab mob tsis zoo exosomal PD-L1, PD-L1-cov neeg mob zoo tau muaj luv luv tom qab kev phais (9.5 feem pua). hli vs 21.7 hli, P<0.001). in="" addition,="" δexopd-l1="" levels="" before="" and="" after="" treatment="" can="" be="" used="" to="" predict="" prognosis="" in="" melanoma="" studies,="" and="" patients="" with="" δexopd-l1="">100 tau luv luv tag nrho cov ciaj sia taus thiab tsis muaj kev vam meej tshaj li cov uas ΔExoPD-L1<100 (p="0.048," 0.011),="" indicating="" that="" the="" amount="" of="" changes="" in="" circulating="" exosomal="" pd-l1="" before="" and="" after="" treatment="" has="" an="" important="" value="" in="" prompting="">

costancheua tauzoo tiv thaiv qog